Power to distinguish BCP-ALL cells from their nearest normal BCP counterpart using the EuroFlow BCP-ALL MRD tubes. Data reflect the percentage of patients that reached the specified score, obtained as described in supplemental Figure 1. Briefly, for each patient, BCP-ALL cells and their nearest normal BCP subset were visualized in a (nonfixed and balanced) APS plot showing the median, 1 SD curves, and 2 SD curves for both populations. Each patient was subsequently scored as follows: no overlap between 2 SD curves: 3 points; overlap of the 2 SD curves: 2 points; overlap of the 2 SD and the 1 SD curve: 1 point; overlap of both 1 SD curves: 0 points. Max, the maximal score of the individual tubes. Phase 1: 7 normal/reactive BM samples and 61 BCP-ALL patients; phase 2: 7 normal BM samples, 4 regenerating BM samples, and 28 BCP-ALL patients; phase 3: 5 normal/reactive BM samples, 9 regenerating BM samples, and 78 BCP-ALL patients; phase 4: 10 normal/reactive BM samples and 83 BCP-ALL patients.